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Abstract
While many patients have substantial residual kidney function (RKF) when initiating hemodialysis 
(HD), most patients with end stage renal disease in the United States are initiated on a three-times 
per week conventional HD regimen, with little regard to RKF or patient preference. RKF is 
associated with many benefits including survival, volume control, solute clearance and reduced 
inflammation. Several strategies have been recommended to preserve RKF after HD initiation, 
including an incremental approach to HD initiation. Incremental HD prescriptions are 
personalized to achieve adequate volume control and solute clearance with consideration to a 
patient’s endogenous renal function. This allows the initial use of less frequent and/or shorter HD 
treatment sessions. Regular measurement of RKF is important because HD frequency needs to be 
increased as RKF inevitably declines. We narratively review the results of 12 observational cohort 
studies of twice weekly compared to thrice weekly HD. Incremental HD is associated with several 
benefits including preservation of RKF as well as extending the event-free life of arteriovenous 
fistulas and grafts. Patient survival and quality of life, however, has been variably associated with 
incremental HD. Serious risks must also be considered, including increased hospitalization and 
mortality perhaps related to fluid and electrolyte shifts after a long inter-dialytic interval. Based on 
the above literature review, and our clinical experience, we suggest patient characteristics which 
may predict favorable outcomes with an incremental approach to HD. These include substantial 
RKF, adequate volume control, lack of significant anemia/electrolyte imbalance, satisfactory 
health related quality of life, low comorbid disease burden and good nutritional status without 
evidence of hypercatabolism. Clinicians should engage patients in on-going conversations to 
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prepare for incremental HD initiation and to ensure a smooth transition to thrice weekly HD when 
needed.
Keywords
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INTRODUCTION
In the United States, there are currently over 450,000 prevalent hemodialysis (HD) patients, 
and a million more are expected to initiate HD in the next decade1. Many patients who 
initiate HD have substantial residual kidney function (RKF)2. In the United States, more 
than 90% of end stage renal disease (ESRD) patients new to hemodialysis initiate a 
standardized three-times per week HD prescription3 with little consideration to RKF, patient 
preference or lifestyle. This is despite the continuing evolution of medical care towards a 
personalized and individual approach.
The dogma of three times a week HD frequency is based on a target Kt/Vurea (urea clearance 
normalized to its volume of distribution). This concept of dialysis adequacy was developed 
in the early 1980s. Patient outcomes were studied initially in the NCDS study4, and 
subsequently in the HEMO trial5. Both of these landmark trials used a thrice-weekly HD 
prescription for all study arms, and enrolled study patients had little or no RKF (creatinine 
clearance ≤ 3 ml/minute in the NCDS study and urea clearance ≤ 1.5 ml/min per 35 L body 
water in the HEMO study). Yet results from these landmark studies led to adequacy 
guidelines6,7 which were clinically applied to most incident HD patients, many who had 
substantial RKF2. While the most recent KDOQI adequacy guidelines now advise that HD 
frequency may be reduced in the presence of substantial RKF8, clinical practice continues to 
lag behind and the vast majority of HD patients remain on a thrice weekly HD regimen9,10.
The prognosis for ESRD patients on dialysis remains grim. While mortality has modestly 
improved in the past decade, maintenance dialysis patients still have an approximately 6 to 8 
times higher risk of mortality than the general Medicare population11. The median life 
expectancy for an incident HD patient is only 3 years1. Hospitalizations in patients on HD 
also remain high, with an average of 1.7 hospitalizations per year and a 35% risk of 30-day 
readmission to hospital12, more than double that of the general Medicare population13. 
Health related quality of life is also substantially lower in ESRD patients than the general 
population14, a finding which remained consistent across 3 continents in one study from the 
Dialysis Outcomes and Practice Patterns Study (DOPPS).
Given the poor prognosis and lack of convincing evidence that a HD prescription based 
solely on raising Kt/Vurea can benefit patient mortality and quality of life, there should be a 
shift away from a “one size fits all” protocolized HD initiation toward a more personalized 
approach to account for unique patient factors including RKF. In this review, we will first 
discuss the importance of RKF to improve patient outcomes, and predictors for loss of RKF. 
We will then summarize the available evidence for incremental HD, and discuss the potential 
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benefits and risks. Finally, we will provide our opinion on specific patient characteristics 
which may predict for favorable outcomes with incremental HD initiation.
THE IMPORTANCE OF RESIDUAL KIDNEY FUNCTION
RKF has been associated with numerous patient benefits, including survival, volume control 
and reduced inflammation. While HD by nature is intermittent, native kidney function is 
continuous. For this reason, even a small amount of residual kidney function contributes to 
reduced plasma levels of solutes that are cleared poorly by HD, such as B2-microglobulin 
and protein bound solutes15–18. RKF has long been utilized in determining the optimal dose 
among patients receiving peritoneal dialysis (PD)19 and has been reported in observational 
studies as an independent predictor of survival in PD20–23.
In HD patients, an understanding of the importance of RKF is still emerging. Less than 5% 
of HD patients have measured RKF24, which may be related to difficulties with accurate 
inter-dialytic urine collection24. Despite this, several observational studies25–29 have found 
independent associations with measures of increased RKF and survival. For example, in a 
recent longitudinal cohort of 5686 patients initiating maintenance dialysis, higher RKF at 1 
year was associated with better survival, with a linear association between mortality and 
both renal urea clearance and urine volume29.
In another prospective study of 1191 HD and 609 PD patients initiating dialysis, anuria was 
found to be associated with a 1.5 times higher risk of mortality than patients with RKF. 
Importantly, this survival benefit did not differ significantly between PD and HD patients27. 
HD patients with RKF also have the advantage of improved volume control. This may 
benefit patients in several ways, including lower ultrafiltration volumes during each dialysis 
session, less intradialytic hypotension, myocardial stunning30,31, and subsequent reduction 
in cardiovascular mortality32,33.
RKF may also play a role in reduction of inflammatory markers34,35, including C-reactive 
protein and interleukin-636; this has been observed in nephrectomized rats through a 
reduction in clearance of inflammatory markers37,38. RKF has been associated with several 
other benefits to HD patients, including better quality of life39, better overall nutritional 
status40, less anemia with less use of epoetin alpha36, and better control of serum 
phosphorus41.
A number of factors can affect the rate of RKF decline once dialysis has been initiated, and 
these can be broadly classified as demographic characteristics, comorbid diseases, or HD 
prescription characteristics. Much of this literature is limited in comparability due to lack of 
a standard definition for RKF and retrospective study designs. With respect to demographic 
characteristics, non-white race has been associated with faster RKF decline24. Gender has a 
variable association, with one analysis of USRDS data reporting female sex associated with 
faster RKF decline24 while another study reported male sex predicted decline in RKF42. Co-
morbid conditions of diabetes43, poorly controlled hypertension and cardiovascular disease 
have all been reported to predict loss of RKF. Intradialytic hypotension during the first 3 
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months of dialysis is also associated with RKF decline, as is the presence of proteinuria, 
even after 6 months after dialysis initiation25.
Certain HD prescription characteristics, including use of high-flux, biocompatible dialysis 
membranes44–46, ultrapure dialysate47 and online hemodiafiltration,48 may slow the decline 
of RKF. Finally, high frequency of dialysis treatments accelerates RKF decline. In a 
secondary analysis of the Frequent Hemodialysis Network (FHN) study49, 67% of incident 
HD patients randomized to frequent nocturnal HD (i.e > 4 times per week) had urine output 
decline to zero, compared to only 32% of control patients on thrice weekly HD.
INCREMENTAL HEMODIALYSIS – WHAT IS IT AND WHAT IS THE 
EVIDENCE?
While robust estimates of the incidence and prevalence of incremental HD in current 
practice patterns are lacking, a historic United States cohort documented 6.1% of incident 
and 2.7% of prevalent HD patients were treated with a twice-weekly HD regimen in 19939. 
A more recent DOPPS study compared the prevalence of twice weekly HD across several 
countries, and found one quarter of Chinese patients were treated with twice weekly HD in 
2011, compared to < 5% across 11 other countries including the United States, Canada, 
France, Italy and Japan10.
Incremental HD prescriptions are personalized to achieve adequate volume control and 
solute clearance with consideration of a patient’s endogenous renal function. This 
individualization of the HD prescription allows for the initial use of shorter duration, less 
frequent and less intense dialysis (i.e. smaller dialyzer surface areas and lower blood and 
dialysate flows)50–52. RKF, along with patient symptoms and inter-dialytic weight gains, 
must be regularly monitored, with adjustment to the HD prescription as RKF declines and/or 
a change in patient factors. Using the recommended fixed target stdKt/V (dialysis + residual 
renal) of 2.38, a conceptual scheme for transition to thrice weekly dialysis using an 
incremental approach is shown in Figure 1. Once or twice-weekly dialysis can also be 
considered as part of a decremental approach to HD in terminally ill patients as they 
transition to end-of-life palliative care52,53.
While RKF has a long history of inclusion into the overall calculation of peritoneal dialysis 
adequacy, it has been largely ignored when initiating and prescribing HD. This may be in 
part due to the HD urea-based “adequacy” targets set forth by the Centers for Medicare and 
Medicaid Services Quality Incentive Program, which do not include residual urea clearance 
(KRU). As such, historical interest in individualizing the HD prescription based on RKF, as 
well research assessing the efficacy and outcomes of incremental HD, has been lacking.
There are several small single center cohort studies comparing twice and thrice weekly HD 
that suggest that twice weekly HD may be associated with a slower decline in RKF 
compared to thrice-weekly HD54–57 (Table 1). For example, in a Shanghai based study55, 30 
HD patients initiated on a twice-weekly HD prescription were compared to 55 patients 
initiated on thrice-weekly HD. RKF loss was significantly higher in the thrice-weekly group 
compared to the twice-weekly group, with an odds ratio of RKF loss for each additional HD 
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treatment per week of 7.2, suggesting that thrice-weekly HD during the first year of dialysis 
was associated with a 7 times higher risk of RKF loss than twice weekly HD. However, 
small sample sizes and lack of reporting on patient survival complicate interpretation of 
these results and limit application to clinical practice.
Recent shifts in clinical practice towards a new paradigm of “personalized medicine”, and 
the 2015 KDOQI adequacy guidelines which advise consideration of incremental HD in the 
presence of substantial RKF8, have prompted larger observational studies with more 
rigorous analysis (Table 1). For example, a large cohort study of 351 incremental HD 
patients and 8068 matched thrice-weekly HD patients assessed the outcomes of decline in 
RKF and mortality28. Substantial RKF was defined as renal urea clearance >3.0mL/min/
1.73m2, or urine volume of >600mL/day. Older patients and non-Hispanic white patients 
were more likely, whereas non-Hispanic black patients and those with a CVC were less 
likely, to receive twice weekly HD. After matching, variables which remained imbalanced 
included weekly IDWG, dialysis treatment time, standard Kt/V delivered by dialysis. The 
results demonstrated that compared with the thrice weekly patients, twice-weekly HD 
patients had 16% (95% CI, 5%–28%) and 15% (95% CI, 2%–30%) more preserved renal 
urea clearance and urine volume, respectively.
The presence of RKF also modified the association of an incremental HD regimen with 
mortality. Incremental HD patients showed similar survival among patients with substantial 
RKF at baseline (HR, 0.99; 95% CI, 0.76–1.28), but higher mortality risk if they had 
inadequate baseline renal urea clearance (≤ 3.0 mL/min/1.73 m2; HR, 1.61; 95% CI, 1.07–
2.44). Results were similar with stratification by baseline urine volume of 600 mL/d. The 
authors concluded that in patients with substantial RKF, incremental HD can be considered 
as a safe option and is associated with greater preservation of RKF. However, use of 
incremental HD in patients with inadequate RKF may prove harmful.
In another recent large observational study58 of 434 incremental HD patients matched to 
50,162 thrice weekly HD patients, the outcome of mortality adjusted for RKF was assessed. 
Incremental HD patients were older and had with less co-morbidity than thrice-weekly HD 
patients. RKF was defined as residual renal urea clearance and calculated using the 
Daugirdas approach59,60. After matching, incremental HD patients compared to thrice 
weekly patients still had higher renal urea clearance (5.4 vs 3.1 mL/min/1.73m2). Mortality 
was similar in the incremental versus thrice-weekly HD groups (HR 0.88; 95% CI 
0.72,1.08). In a pre-specified subgroup analysis of patients with a high Charleston Co-
morbidity index ≥ 5, incremental HD patients had a 1.7-fold higher mortality than thrice 
weekly HD patients (HR 1.77, 95% CI 1.20, 2.62).
While these larger studies provide a more rigorous analytic approach, the observation design 
has inherent limitations including residual confounding by indication and lack of prospective 
data collection of all important variables. A randomized controlled trial has not yet been 
conducted comparing twice to thrice weekly HD, and would shed light on the safety and 
efficacy of incremental HD in select patient populations.
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POTENTIAL BENEFITS OF INCREMENTAL HD
Incremental HD has many potential benefits to patients, clinicians and health systems. 
Preservation of RKF is important in incident HD patients and is associated with many 
benefits including patient survival, better quality of life, improved overall nutritional status 
and less anemia (see above, The Importance of Residual Kidney Function). Another benefit 
of incremental HD is longevity of vascular access related to less frequent arteriovenous 
fistula or graft cannulations. In an analysis from the FHN study, more frequent HD reduced 
the composite endpoint of vascular access loss, repair or access-related hospitalization. The 
risk for a first access event was 76% higher with daily HD than with conventional HD (HR 
1.76; 95% CI, 1.11–2.79; P=0.017)61. Economic benefits must also be considered with less 
frequent HD treatment regimens. Conventional thrice weekly HD treatments costs 
approximately $89,000 per patient annually in the United States, with a total annual cost of 
$42 billion ($34 billion paid by Medicare, the remainder by Medicaid, private insurance or 
out-of-pocket payments)62.
Perhaps through the mechanism of RKF preservation, longer patient survival has been 
observed with incremental HD in some studies, and survivals similar to those of thrice 
weekly HD have been noted in other studies (see Table 1). This variable effect of 
incremental HD on mortality may be related to a beneficial modifying effect of RKF28, 
which is not accounted for in all studies. However, it is important to note that these 
associations have only been reported in observational studies.
Clinicians may intuit that patients choose twice weekly HD for convenience and improved 
quality of life. While robust prospective studies are lacking, a recent DOPPS study examined 
HD patient characteristics and health related quality of life (HRQOL) in China (where over 
one quarter of HD patients are dialyzed twice weekly). In 304 patients on a twice weekly 
HD regimen and 982 patients on a thrice weekly regimen, there was no significant difference 
in HRQOL, measured using the KDQOL Short Form 1210.
POTENTIAL RISKS AND BARRIERS TO INCREMENTAL HD
Without careful evaluation and discussion between physician and patient, the broad use of 
incremental HD can potentially be associated with several risks. In addition to less solute 
clearance, of particular concern is the longer inter-dialytic interval with less frequent 
HD63–65. In the landmark study by Foley et al64 of 32,065 patients on conventional thrice 
weekly HD, all-cause mortality was significantly higher on the day after the long, 2-day 
inter-dialytic interval compared to other days (22.1 vs 18.0 deaths per 100 person years, 
p<0.001). This increased mortality is presumably related to rapid fluid shifts, with 
subsequent myocardial stunning and cardiac adverse events66,67. Large inter-dialytic weight 
gains over the 2-day interval would necessitate rapid ultrafiltration rates (≥10mL/kg/hr)68, 
which has been independently associated with mortality.
Similarly, rapid electrolyte shifting is also associated with adverse outcomes. Brunelli et al 
recently studied 52,734 thrice-weekly HD patients69, and reported elevated serum potassium 
levels of 5.5 to <6.0 mEq/L obtained on Friday were associated with highest magnitude of 
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hospitalization risk within 4 days of measurement (OR, 1.68, 95% CI, 1.22–2.30), compared 
to levels obtained on Monday or Wednesday.
It is important to note that the study cohort in both of these analyses was comprised on 
prevalent HD patients, who likely had minimal or non-existent RKF. Presence of substantial 
RKF in a patient on HD may contribute to fluid and electrolyte control on non-dialysis days, 
and mitigate the rapid ultrafiltration and electrolyte shifts after a long inter-dialytic interval.
While there has been recent renewed interest in preservation of RKF in ESRD patients, 
barriers remain for widespread use of an incremental approach to HD. Firstly, there are 
alternative means to potentially slow the decline of RKF once HD is initiated, including: 1) 
avoidance of nephrotoxins70,71 (aminoglycosides, non-steroidal anti-inflammatories, 
radiocontrast dye), 2) control hypertension while minimizing intradialytic hypotension 72,73, 
3) adjustment of the HD prescription (high-flux biocompatible dialyzer membranes and 
ultra-pure dialysate water)44,74,75, and 4) possible consideration of a low protein diet (0.6 to 
0.8g/kg/day) on non-dialysis days56,76,77.
We believe these tactics are important, and should be used whenever possible and 
appropriate. However, the modifying effect of RKF on the association of incremental HD 
and survival 28 provides a potent rationale for incorporating this incremental HD strategy 
into an attentive and thoughtful approach for RKF preservation.
Secondly, clinicians may have concerns about the practicalities on how or when to increase 
HD frequency, especially related to patient adherence with changing HD treatment 
frequency. Clinicians must actively engage patients and their caregiver(s) in the shared 
decision-making process with incremental HD transitions with ongoing conversations over 
multiple sessions. Clear expectations prior to HD initiation and each frequency change are 
critical in order to ensure a smooth patient transition from twice to thrice weekly HD. 
Golper provides a practical approach, with a case example dialogue, regarding the need to 
increase HD frequency from twice to three times per week50. In addition, an HD patient’s 
RKF must be monitored regularly while on a twice-weekly regimen. Monthly timed urine 
collections for residual creatinine and urea clearance are advised, although some experts 
recommend urine volume may be an appropriate surrogate measure52.
Finally, some HD outpatient facilities in the private sector may perceive loss of dialysis 
treatment income with a shift to twice weekly treatments, and pose barriers to its 
implementation. Pragmatic and innovative solutions, such as scheduling shifts, can 
accommodate the same number of HD treatments for incremental HD patients. For example, 
3 twice weekly patients could be scheduled on Mon-Thu, Tue-Fri and Wed-Sat in lieu of 2 
thrice-weekly patients78.
OUR OPINION
Incremental HD is not suitable for all patients with ESRD, and requires a judicious and 
attentive clinical approach for successful implementation. The KDOQI 2015 clinical 
practice guidelines update for HD adequacy do not provide a clear approach for its use 8. 
The ungraded KDOQI recommendations are: 1) In patients with significant residual native 
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kidney function (Kr), the dose of HD may be reduced provided Kr is measured periodically; 
and 2) For HD schedules other than thrice weekly, a target standard Kt/V of 2.3 volumes per 
week with a minimum delivered dose of 2.1 using a method of calculation that includes the 
contributions of ultrafiltration and residual kidney function. Based on our clinical experience 
and review of the literature, we provide our opinion on treatment criteria and for incremental 
HD in order to clarify the current clinical practice guidelines.
Treatment Criteria for Twice Weekly HD
Careful patient selection for initiation of an incremental approach to HD is crucial to 
maximize treatment success and maintain patient quality of life. These recommendations are 
based on clinical criteria set forth by Kalantar-Zadeh et al52 where decision support is 
provided for incremental HD.
1. Substantial RKF: We believe this is the most important clinical criteria to 
determine HD frequency. The 2006 KDOQI guidelines suggest a minimum 
session single pool Kt/V which can be reduced in patients with KRU of > 2 
ml/min per 1.73 m2, but that twice-weekly HD is not recommended unless KRU 
is > 3 ml/min per 1.73 m2. Monthly measurements of RKF are important to avoid 
under-dosing HD as RKF is lost over time. Monthly timed urine collections with 
KRU calculations can be cumbersome, and consideration can be given to a more 
practical approach for monitoring urine volume (i.e target urine volume > 0.5L/
day), along with other important markers of adequacy such as anemia and fluid 
gains. The results from a contemporary cohort study also supported the cutoff of 
3 ml/min per 1.73 m2 for KRU while suggesting 0.6 L/day as an alternative 
target for the urine volume-based approach28.
2. Infrequent hospitalization and manageable co-morbid conditions: It is important 
that patients being considered for infrequent HD regimens are otherwise in good 
health. Patients with high co-morbid disease burden may have no benefit, and 
may incur harm from a twice weekly HD regimen.
3. Infrequent electrolyte imbalance: We suggest that hyperkalemia (K.5.5mEq/L) 
and hyperphosphatemia (P>5.5mg/dL) are infrequent and readily manageable. 
This provides physicians with clinical evidence of substantial RKF and patient 
adherence.
4. Lack of profound anemia: We suggest Hb >8g/L, along with appropriate 
responsiveness to therapy for anemia, as another indicator of good health and 
substantial RKF.
5. Manageable volume status: We believe this can be assessed by limited fluid 
retention between two consecutive HD treatments 3 days apart of <2.5kg (or 5% 
of ideal dry weight), in addition to limited or readily manageable cardiovascular/
pulmonary symptoms of fluid overload.
6. Good nutritional status and lack of hypercatabolic state: Since clinicians may 
choose to implement a low-protein diet along with twice weekly HD to preserve 
RKF, underlying good nutritional status is important. In addition, we believe that 
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infrequent dialysis in the setting of unmitigated catabolism will have negative 
consequences on HD adequacy, since solutes and toxins are produced and 
retained beyond those from dietary protein intake.
7. Satisfactory health related quality of life: We believe that a detailed assessment 
of patients’ quality of life prior to initiation of an incremental approach to HD is 
vital. A patient’s underlying psychological well-being may help alleviate a 
negative response when frequency of HD is increased.
CONCLUSION
In summary, incremental HD provides patients with an individualized approach to the 
initiation of HD. This approach has many potential benefits, but may increase health-related 
risks in patients who are not judiciously selected, educated and will participate in a shared 
decision-making process with their treating nephrologist. While several large observational 
studies have demonstrated benefit in select populations, well-designed clinical trials are still 
needed to determine the safety, efficacy and optimal patient characteristics to optimize 
outcomes with an incremental HD approach.
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Figure 1. 
A conceptual scheme for an incremental hemodialysis regimen with adjustment of 
hemodialysis frequency based on residual renal urea clearance. (used with permission, 
Kidney International Reports and the International Society of Nephrology)
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